research Phenotypic Analysis of T-Cells in Extensive Alopecia Areata Scalp Suggests Partial Tolerance
T-cells in alopecia areata scalp show abnormal regulation, leading to less inflammation.
Search
for
Sort by
Research
990-1000 / 1000+ resultsresearch Second-to-fourth digit ratio and age predicting the severity of androgenetic alopecia: a cross-sectional study
Lower 2D:4D ratio and older age increase the risk of severe hair loss in men.
research Efficacy and safety of tofacitinib in patients with total and universal alopecia- A retrospective evaluation of 69 patients
Tofacitinib is effective for treating alopecia totalis and universalis, with some patients experiencing significant hair regrowth.
research Thyrotropin releasing hormone (TRH): a new player in human hair‐growth control
TRH stimulates human hair growth and extends the hair growth phase.
research Contribution à l'étude du lien entre Annonaceae et parkinsonisme : identification et quantification d'acétogénines par déréplication; métabolisation de phase I et approche de la distribution de l'annonacine
Thymosin β4 helps with healing, inflammation, and organ protection.
research Tumid Lupus Erythematosus and Systemic Lupus Erythematosus: A Report on Their Rare Coexistence
A woman with both TLE and SLE improved with hydroxychloroquine treatment.
research Toll-like receptor-targeted anti-tumor therapies: Advances and challenges
TLR-targeted therapies show promise in cancer treatment by helping destroy tumors.
research Analysis of the changes in scalp hair angles: In vivo and in vitro comparison before and after tumescence
Tumescent fluid increases scalp hair angles, which may improve hair transplant results and reduce surgeon fatigue.
research 586 Increase in CD8+ effector memory cells re-expressing CD45RA (TEMRA) reflects disease activity and enables early prediction of therapeutic outcome in rapidly progressive alopecia areata
Increased TEMRA cells can predict treatment outcomes in rapidly progressive alopecia areata.
research Sacituzumab tirumotecan (sac-TMT/MK-2870/SKB264): a novel antibody–drug conjugate in breast cancer
Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.